Your browser doesn't support javascript.
loading
Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis: results from the 52-week, Phase III China-centric study, MEASURE 5 / 中华医学杂志(英文版)
Chinese Medical Journal ; (24): 2521-2531, 2020.
Article in English | WPRIM | ID: wpr-877834
ABSTRACT
BACKGROUND@#Secukinumab demonstrated sustained efficacy in patients with ankylosing spondylitis (AS) through 5 years in pivotal Phase III studies. Here, we present efficacy and safety results (52-week) of secukinumab in patients with AS from the MEASURE 5 study.@*METHODS@#MEASURE 5 was a 52-week, Phase III, China-centric study. Eligible patients were randomly assigned (21) to receive subcutaneous secukinumab 150 mg or placebo weekly for the first five doses and then once every 4 weeks (q4w). All placebo patients switched to secukinumab 150 mg q4w starting at Week 16. Primary endpoint was Assessments of SpondyloArthritis international Society (ASAS) 20 at Week 16. Randomization was stratified by region (China vs. non-China).@*RESULTS@#Of 458 patients (secukinumab 150 mg, N = 305; placebo, N = 153) randomized, 327 (71.4%) were from China and 131 (28.6%) were not from China. Of these, 97.7% and 97.4% patients completed Week 16 and 91.1% and 95.3% (placebo-secukinumab) patients completed Week 52 of treatment. The primary endpoint was met; secukinumab significantly improved ASAS20 response at Week 16 vs. placebo (58.4% vs. 36.6%; P < 0.0001); corresponding rate in the Chinese population was 56.0% vs. 38.5% (P < 0.01). All secondary efficacy endpoints significantly improved with secukinumab 150 mg in the overall population at Week 16; responses were maintained with a trend toward increased efficacy from Week 16 to 52. No new or unexpected safety signals were reported up to Week 52.@*CONCLUSIONS@#Secukinumab 150 mg demonstrated rapid and significant improvement in signs and symptoms of AS. Secukinumab was well tolerated and the safety profile was consistent with previous reports. Efficacy and safety results were comparable between the overall and Chinese populations.@*TRIAL REGISTRATION@#ClinicalTrials.gov, NCT02896127; https//clinicaltrials.gov/ct2/show/NCT02896127?term=NCT02896127&draw=2&rank=1.
Subject(s)
Full text: Available Index: WPRIM (Western Pacific) Main subject: Spondylitis, Ankylosing / China / Double-Blind Method / Treatment Outcome / Antibodies, Monoclonal, Humanized / Antibodies, Monoclonal Type of study: Controlled clinical trial / Diagnostic study Limits: Humans Country/Region as subject: Asia Language: English Journal: Chinese Medical Journal Year: 2020 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Main subject: Spondylitis, Ankylosing / China / Double-Blind Method / Treatment Outcome / Antibodies, Monoclonal, Humanized / Antibodies, Monoclonal Type of study: Controlled clinical trial / Diagnostic study Limits: Humans Country/Region as subject: Asia Language: English Journal: Chinese Medical Journal Year: 2020 Type: Article